Healthcare of Ontario Pension Plan Trust Fund Has $2.05 Million Stock Position in DaVita Inc. $DVA

Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in DaVita Inc. (NYSE:DVA) by 855.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 13,327 shares of the company’s stock after purchasing an additional 11,932 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in DaVita were worth $2,048,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Root Financial Partners LLC lifted its holdings in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares in the last quarter. Caitlin John LLC bought a new stake in DaVita during the fourth quarter worth $34,000. Canada Pension Plan Investment Board bought a new stake in DaVita during the second quarter worth $43,000. Sankala Group LLC purchased a new stake in DaVita in the 4th quarter valued at $39,000. Finally, iSAM Funds UK Ltd bought a new position in DaVita during the 3rd quarter valued at $46,000. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

NYSE DVA opened at $240.00 on Friday. The company has a market capitalization of $15.41 billion, a PE ratio of 22.26, a price-to-earnings-growth ratio of 0.78 and a beta of 0.88. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $244.49. The company has a 50-day simple moving average of $217.76 and a 200 day simple moving average of $173.13.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the firm earned $2.00 EPS. The company’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DVA. UBS Group upped their target price on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Barclays boosted their price target on shares of DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 8th. TD Cowen upped their price objective on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Finally, Truist Financial lifted their target price on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $216.50.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is currently owned by corporate insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.